- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Dendreon Corp (DNDN)
| Open: | 7.2200 | Day's Range: | 7.0700 - 7.3500 | Volume: | 4,107,307 | Bid: | 7.1000 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 7.2200 | 52wk Range: | 6.4600 - 42.8700 | 1-Yr Rtn: | -83.22% | Ask: | 7.1100 |
Key Statistics for DNDN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -1.9700 |
| Est. EPS (USD) (12/2012) | -2.1170 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,094.90 |
| Shares Outstanding (M) | 153.99 |
| Enterprise Value (M USD) (ttm) | 1,171.17 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 3.9173 |
| Price/Sale (ttm) | 2.6219 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/03/2012 |
More DNDN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for DNDN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for DNDN
Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer.
| Mitchell H Gold "Mitch"Chairman | John H JohnsonPresident/CEO |
| Gregory T SchiffmanExec VP/CFO/Treasurer | Christine MikailExec VP:Dev/Secy/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page